產品屬性：
產品名稱 | Dalbavancin hydrochloride |
規格 | 10mM*1 mL in DMSO、1mg、5mg、10mg、25mg、50mg、100mg |
貨號 | EY-01Y10224 |
Cas No.: 2227366-51-8
別名: N/A
化學名: N/A
分子式: C88H101Cl3N10O28
分子量: 1853.15
溶解度: H2O: 50 mg/mL (26.98 mM); DMSO: ≥ 24 mg/mL (12.95 mM)
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
Dalbavancin hydrochloride (MDL-63397 hydrochloride) is a semisynthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin hydrochloride inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively[1][2].Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci, organisms against which it has shown greater potency than existing glycopeptide therapeutic agents[1][2].Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens[1]. Animal Model:Female BALB/c mice (6-8 weeks) challenged with Ames strain of B. anthracis[1][1]. Heine HS, et al. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Antimicrob Agents Chemother. 2010 Mar;54(3):991-6.[2]. Bennett JW, et al. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag. 2008 Feb;4(1):31-40.
特別提醒公司產品僅供科研使用
